Aerovate Therapeutics Inc

NASDAQ AVTE

Download Data

Aerovate Therapeutics Inc Total Liabilities to Total Assets Ratio 3 year CAGR for the year ending December 31, 2023: -66.74%

Aerovate Therapeutics Inc Total Liabilities to Total Assets Ratio 3 year CAGR is -66.74% for the year ending December 31, 2023, a 2.67% change year over year. The total liabilities to total assets ratio measures the proportion of total liabilities to total assets. It is calculated by dividing the total liabilities by the total assets. This ratio provides insights into the company's financial leverage and the proportion of its assets financed by liabilities. A higher ratio indicates a higher level of financial risk and reliance on liabilities for asset acquisition. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Aerovate Therapeutics Inc Total Liabilities to Total Assets Ratio for the year ending December 31, 2022 was 0.06, a 276.64% change year over year.
  • Aerovate Therapeutics Inc Total Liabilities to Total Assets Ratio for the year ending December 31, 2021 was 0.02, a -99.56% change year over year.
  • Aerovate Therapeutics Inc Total Liabilities to Total Assets Ratio for the year ending December 31, 2020 was 3.83, a 88.05% change year over year.
  • Aerovate Therapeutics Inc Total Liabilities to Total Assets Ratio for the year ending December 31, 2019 was 2.04.
NASDAQ: AVTE

Aerovate Therapeutics Inc

CEO Mr. Timothy P. Noyes M.B.A.
IPO Date June 30, 2021
Location United States
Headquarters 930 Winter Street, Waltham, MA, United States, 02116
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email